Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marzia Capelletti

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Breast (Edinburgh, Scotland)|January 30, 2007
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based studyAntonino Musolino, Maria A Bella, Beatrice Bortesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2016
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Cancer Discovery|June 4, 2015
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung CancerErin M Tricker, Chunxiao Xu, Sharmeen Uddin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerSinead Cuffe, Abderrahmane Bourredjem, Stephen Graziano, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2009
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markersMarcello Tiseo, Giulio Rossi, Marzia Capelletti, et al.
Biochemical Pharmacology|May 12, 2009
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell linesSilvia La Monica, Maricla Galetti, Roberta R Alfieri, et al.
Frontiers in Neurology|January 27, 2023
Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selectionMark Willy L Mondia, Michael A Kritselis, John E Donahue, et al.
Tumori|February 7, 2006
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based studyAntonino Musolino, Maria Michiara, Maria A Bella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trialPasi A Jänne, Xiaofei Wang, Mark A Socinski, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Breast (Edinburgh, Scotland)|January 30, 2007
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based studyAntonino Musolino, Maria A Bella, Beatrice Bortesi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2016
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Cancer Discovery|June 4, 2015
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung CancerErin M Tricker, Chunxiao Xu, Sharmeen Uddin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerSinead Cuffe, Abderrahmane Bourredjem, Stephen Graziano, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2009
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markersMarcello Tiseo, Giulio Rossi, Marzia Capelletti, et al.
Biochemical Pharmacology|May 12, 2009
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell linesSilvia La Monica, Maricla Galetti, Roberta R Alfieri, et al.
Frontiers in Neurology|January 27, 2023
Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selectionMark Willy L Mondia, Michael A Kritselis, John E Donahue, et al.
Tumori|February 7, 2006
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based studyAntonino Musolino, Maria Michiara, Maria A Bella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trialPasi A Jänne, Xiaofei Wang, Mark A Socinski, et al.
Pageof 6